ClinicalTrials.gg
CompletedNCT00398476Updated Mar 1, 2018Results posted

Fluticasone Nasal Spray Patient Preference Study

A Phase 3 interventional study of fluticasone propionate (FP) and fluticasone furoate (FF) in Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial — 1 open to participants now, 1 under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Perennial.

Enrollment
13th of 21
127 · median 288
Started
2006
with 1 other
Phase 3
12 of 21
none open now
Registered
9th of 21
by date
Lead sponsor
18 of 21
GlaxoSmithKline

Among the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, this one is the 13th largest by enrollment, is one of 2 that started in 2006, is one of 12 in phase 3, and was the 9th registered.

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Open to participants now

1 of the 21 studies testing fluticasone in Rhinitis, Allergic, Perennial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing fluticasone in Rhinitis, Allergic, Perennial, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate and compare patient preference for FF (Fluticasone Furoate) and FP (Fluticasone Propionate Aqueous)nasal sprays in the treatment of allergic rhinitis following single-dose administration.

03

Conditions studied

  • Rhinitis, Allergic, Perennial

Keywords

  • taste
  • questionnaire
  • preference
  • attributes
  • odor
  • after taste
  • scent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • allergic rhinitis
  • literate

Exclusion criteria

Exclusion Criteria:

  • clinical significant uncontrolled disease
  • Use of intranasal (\<4 weeks of FP [branded or generic],\<4 week exposure to FF, \<4 weeks use of other INS)
  • Use of intranasal medications \<1 week
  • Use of meds that significantly inhibit CYP4503A4
  • Use of perfume or oral rinse on study day
  • Allergy/intolerance to INS, antihistamines, or
  • Positive pregnancy test or female who is breastfeeding
  • Affiliation with site
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Enrollment
127 participants (actual)

Study arms

  • Active comparator
    fluticasone propionate (FP)

    200 micrograms (mcg); an aqueous suspension of microfine FP

    Drug: fluticasone propionate (FP)

  • Active comparator
    fluticasone furoate (FF)

    110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF

    Drug: fluticasone furoate (FF)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Participants Preference for Nasal Spray Based on Selected Product Attributes at the End of Crossover Dosing

    An overall preference questionnaire (OPQ) was used to evaluate participant's preference for nasal spray therapy for the given treatments. OPQ allows the responder three options, based on products attributes, i.e. preference for product 1 (FF 110 µg); preference for product 2 (FP 200 µg) and no preference. Three participant-related questionnaires were completed during the course of the study, including two attributes questionnaires : Immediate attributes questionnaire (IAQ) and delayed attributes questionnaire (DAQ). An OPQ was completed upon completion of the crossover dosing.

    Time frame: Day 1

Secondary outcomes

  1. Number of Participants With Preference for Scent/Odor in IAQ and DAQ

    Participant preference for scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did product have a scent/odor?. Participants specified their responses on a 6-point scale: 0: none; 1: very mild; 2: mild; 3: neither mild nor strong; 4: slightly strong; 5; moderately strong; 6: very strong. Higher score indicated strong odor.

    Time frame: Day 1

  2. Number of Participants With Preference for Satisfaction With Scent/Odor in IAQ

    Participant preference for Satisfaction scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied with scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

    Time frame: Day 1

  3. Number of Participants With Preference for Satisfaction With Scent/Odor in DAQ

    Participant preference for Satisfaction scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: How satisfied with scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

    Time frame: Day 1

  4. Number of Participants Who Satisfied Not to Have Scent/Odor in IAQ

    Participant preference for participants who satisfied not to have scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied not to have scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

    Time frame: Day 1

  5. Number of Participants Who Satisfied Not to Have Scent/Odor in DAQ

    Participant preference for participants who satisfied not to have scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: How satisfied not to have scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

    Time frame: Day 1

  6. Number of Participants Reported Product Have an Immediate Taste in IAQ

    Participant preference for an immediate taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: Did product have an immediate taste?. Participants specified their responses on a on a 6-point scale: 0: no; 1: very mild; 2: mild; 3: neither mild nor strong; 4: slightly strong; 5; moderately strong; 6: very strong.

    Time frame: Day 1

  7. Number of Participants Satisfied With an Immediate Taste in IAQ

    Participant preference for satisfaction with an immediate taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied with immediate taste?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

    Time frame: Day 1

  8. Number of Participants Reported Product Have an After Taste in DAQ

    Participant response for an after taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: Did product have an aftertaste?. Participants specified their responses on a 6-point scale: 0: No aftertaste; 1: Very mild; 2: Mild; 3: Neither mild nor strong; 4: Slightly strong; 5: Moderately strong; 6: Very strong.

    Time frame: Day 1

  9. Number of Participants Satisfied With an After Taste in DAQ

    Participant response for satisfaction with an after taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: How satisfied with aftertaste? Participants specified their responses on a 6-point scale: 0: Very satisfied; 1: Moderately satisfied; 2: Somewhat satisfied; 3: Neither satisfied nor dissatisfied; 4: Somewhat dissatisfied; 5: Moderately dissatisfied; 6: Very dissatisfied.

    Time frame: Day 1

  10. Number of Participants Reported Medicine Run Down Throat in IAQ and DAQ

    Participant response regarding did the medicine run down throat at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did medicine run down throat? Participants specified their responses on a 6-point scale: 0: None; 1: Very slightly; 2: Slightly; 3: Neither slightly nor moderately; 4: Moderately; 5: Markedly; 6: Very markedly.

    Time frame: Day 1

  11. Number of Participants Reported Medicine Run Out of Nose in IAQ and DAQ

    Participant response regarding did the medicine run out of nose at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did medicine run out of nose? Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.

    Time frame: Day 1

  12. Number of Participants Reported Product Feel Soothing in IAQ and DAQ

    Participant response for soothing feel at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did product feel soothing?. Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.

    Time frame: Day 1

  13. Number of Participants Reported Product Make Want to Sneeze in IAQ

    Participant response regarding sneezing effect at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: Did product make want to sneeze?. Participants specified their responses on a 6-point scale: 0: No urgency; 1: Very slight urgency; 2: slight urgency; 3: Neither slight nor moderate urgency; 4: Moderate urgency; 5; Marked urgency; 6: Very marked urgency.

    Time frame: Day 1

  14. Number of Participants Satisfied With Product in DAQ

    Number of participants responding to product satisfaction with delayed attributes questionnaire, Question: How satisfied with product?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

    Time frame: Day 1

  15. Number of Participants Reported Nasal Irritation in DAQ

    Participant response regarding nasal irritation at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: Did product cause nasal irritation?. Participants specified their responses on a 6-point scale: 0: none; 1: very slight; 2: slight; 3: neither slight nor moderate; 4: moderate; 5; marked; 6: very marked.

    Time frame: Day 1

  16. Number of Participants Reported Nasal Irritation Bothersome in DAQ

    Participant response regarding bothersome of nasal irritation at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: How bothersome was nasal irritation?. Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.

    Time frame: Day 1

  17. Number of Participants Comply With Product if Prescribed in DAQ

    Number of participants responding to product attributes using delayed attributes questionnaire, Question: How likely to comply if prescribed?. Participants specified their responses on a 6-point scale: 0: very likely; 1: moderately likely; 2: somewhat likely; 3: neither likely nor unlikely; 4: somewhat unlikely; 5; moderately unlikely; 6: very unlikely.

    Time frame: Day 1

07

Results

Posted Jan 29, 2018

Participant flow

A total of 127 male or eligible female participants with a diagnosis of allergic rhinitis were enrolled in the study. This study was conducted at 12 investigator sites in the United States. Study duration was '01 December 2006 - 04 December 2006'. Participants included in PP population were 121.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneFF 110 µg /FP 200 µgFP 200 µg /FF 110 µg
Started6364
Completed6364
Not completed00
Washout Period (20 Minutes)
Participant flow — Washout Period (20 Minutes)
MilestoneFF 110 µg /FP 200 µgFP 200 µg /FF 110 µg
Started6364
Completed6364
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneFF 110 µg /FP 200 µgFP 200 µg /FF 110 µg
Started6364
Completed6364
Not completed00

Outcome measures

PrimaryOverall Participants Preference for Nasal Spray Based on Selected Product Attributes at the End of Crossover Dosing

An overall preference questionnaire (OPQ) was used to evaluate participant's preference for nasal spray therapy for the given treatments. OPQ allows the responder three options, based on products attributes, i.e. preference for product 1 (FF 110 µg); preference for product 2 (FP 200 µg) and no preference. Three participant-related questionnaires were completed during the course of the study, including two attributes questionnaires : Immediate attributes questionnaire (IAQ) and delayed attributes questionnaire (DAQ). An OPQ was completed upon completion of the crossover dosing.

Time frame:
Day 1
Reported as:
Number · Participants
Overall Participants Preference for Nasal Spray Based on Selected Product Attributes at the End of Crossover Dosing
ParticipantsOverall Study Arm
Overall, FF 110 µg72
Overall, FP 200 µg39
Overall, No preference9
Scent/odor, FF 110 µg77
Scent/odor, FP 200 µg35
Scent/odor, No preference8
Immediate taste, FF 110 µg56
Immediate taste, FP 200 µg25
Immediate taste, No preference39
After-taste, FF 110 µg53
After-taste, FP 200 µg26
After-taste, No preference41
Less drip down throat, FF 110 µg52
Less drip down throat, FP 200 µg32
Less drip down throat, No preference36
Less run out nose, FF 110 µg59
Less run out nose, FP 200 µg23
Less run out nose, No preference38
More soothing, FF 110 µg45
More soothing, FP 200 µg38
More soothing, No preference37
Less irritating, FF 110 µg41
Less irritating, FP 200 µg26
Less irritating, No preference53
Urge to sneeze, FF 110 µg25
Urge to sneeze, FP 200 µg21
Urge to sneeze, No preference74
Statistical analysis
  • Overall Study Arm · Cochran-Mantel-Haenszel · p = 0.003
  • Overall Study Arm · Cochran-Mantel-Haenszel · p = <0.001
  • Overall Study Arm · Cochran-Mantel-Haenszel · p = <0.001
  • Overall Study Arm · Cochran-Mantel-Haenszel · p = 0.002
  • Overall Study Arm · Cochran-Mantel-Haenszel · p = 0.037
  • Overall Study Arm · Cochran-Mantel-Haenszel · p = <0.001
  • Overall Study Arm · Cochran-Mantel-Haenszel · p = 0.408
  • Overall Study Arm · Cochran-Mantel-Haenszel · p = 0.070
  • Overall Study Arm · Cochran-Mantel-Haenszel · p = 0.587
SecondaryNumber of Participants With Preference for Scent/Odor in IAQ and DAQ

Participant preference for scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did product have a scent/odor?. Participants specified their responses on a 6-point scale: 0: none; 1: very mild; 2: mild; 3: neither mild nor strong; 4: slightly strong; 5; moderately strong; 6: very strong. Higher score indicated strong odor.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants With Preference for Scent/Odor in IAQ and DAQ
ParticipantsFF 110 µgFP 200 µg
IAQ, None6212
DAQ, None7116
IAQ, Very mild2722
DAQ, Very mild2139
IAQ, Mild1935
DAQ, Mild1629
IAQ, Neither mild nor strong27
DAQ, Neither mild nor strong44
IAQ, Slightly strong620
DAQ, Slightly strong620
IAQ, Moderately strong419
DAQ, Moderately strong210
IAQ, Very strong15
DAQ, Very strong13
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = <0.001 · Median difference (final values): -2.0
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = <0.001 · Median difference (final values): -1.0
SecondaryNumber of Participants With Preference for Satisfaction With Scent/Odor in IAQ

Participant preference for Satisfaction scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied with scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With Preference for Satisfaction With Scent/Odor in IAQ
ParticipantsFF 110 µgFP 200 µg
IAQ, Very satisfied1116
IAQ, Moderately satisfied1220
IAQ, Somewhat satisfied1325
IAQ, Neither satisfied nor dissatisfied1617
IAQ, Somewhat dissatisfied623
IAQ, Moderately dissatisfied15
IAQ, Very dissatisfied23
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.255 · Median difference (net): 0.0
SecondaryNumber of Participants With Preference for Satisfaction With Scent/Odor in DAQ

Participant preference for Satisfaction scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: How satisfied with scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With Preference for Satisfaction With Scent/Odor in DAQ
ParticipantsFF 110 µgFP 200 µg
DAQ, Very satisfied1419
DAQ, Moderately satisfied1121
DAQ, Somewhat satisfied1220
DAQ, Neither satisfied nor dissatisfied1022
DAQ, Somewhat dissatisfied516
DAQ, Moderately dissatisfied06
DAQ, Very dissatisfied12
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.056 · Median difference (net): 0.0
SecondaryNumber of Participants Who Satisfied Not to Have Scent/Odor in IAQ

Participant preference for participants who satisfied not to have scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied not to have scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants Who Satisfied Not to Have Scent/Odor in IAQ
ParticipantsFF 110 µgFP 200 µg
IAQ, Very satisfied4610
IAQ, Moderately satisfied72
IAQ, Somewhat satisfied10
IAQ, Neither satisfied nor dissatisfied61
IAQ, Somewhat dissatisfied20
IAQ, Moderately dissatisfied00
IAQ, Very dissatisfied11
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.845 · Median difference (net): 0.0
SecondaryNumber of Participants Who Satisfied Not to Have Scent/Odor in DAQ

Participant preference for participants who satisfied not to have scent/odor at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: How satisfied not to have scent/odor?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants Who Satisfied Not to Have Scent/Odor in DAQ
ParticipantsFF 110 µgFP 200 µg
DAQ, Very satisfied5614
DAQ, Moderately satisfied21
DAQ, Somewhat satisfied40
DAQ, Neither satisfied nor dissatisfied81
DAQ, Somewhat dissatisfied30
DAQ, Moderately dissatisfied00
DAQ, Very dissatisfied10
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.871 · Median difference (net): 0.0
SecondaryNumber of Participants Reported Product Have an Immediate Taste in IAQ

Participant preference for an immediate taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: Did product have an immediate taste?. Participants specified their responses on a on a 6-point scale: 0: no; 1: very mild; 2: mild; 3: neither mild nor strong; 4: slightly strong; 5; moderately strong; 6: very strong.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Reported Product Have an Immediate Taste in IAQ
ParticipantsFF 110 µgFP 200 µg
No taste9869
Very mild taste1025
Mild taste713
Neither mild nor strong taste26
Slightly strong taste36
Moderately strong taste12
Very strong taste00
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = <0.001 · Median difference (net): 0.0
SecondaryNumber of Participants Satisfied With an Immediate Taste in IAQ

Participant preference for satisfaction with an immediate taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: How satisfied with immediate taste?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Satisfied With an Immediate Taste in IAQ
ParticipantsFF 110 µgFP 200 µg
Very satisfied612
Moderately satisfied79
Somewhat satisfied69
Neither satisfied nor dissatisfied915
Somewhat dissatisfied36
Moderately dissatisfied13
Very dissatisfied10
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.592 · Median difference (net): 0.0
SecondaryNumber of Participants Reported Product Have an After Taste in DAQ

Participant response for an after taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: Did product have an aftertaste?. Participants specified their responses on a 6-point scale: 0: No aftertaste; 1: Very mild; 2: Mild; 3: Neither mild nor strong; 4: Slightly strong; 5: Moderately strong; 6: Very strong.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Reported Product Have an After Taste in DAQ
ParticipantsFF 110 µgFP 200 µg
No aftertaste9066
Very mild aftertaste2233
Mild aftertaste710
Neither mild nor strong aftertaste03
Slightly strong aftertaste26
Moderately strong aftertaste03
Very strong aftertaste00
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = <0.001 · Median difference (net): 0.0
SecondaryNumber of Participants Satisfied With an After Taste in DAQ

Participant response for satisfaction with an after taste at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: How satisfied with aftertaste? Participants specified their responses on a 6-point scale: 0: Very satisfied; 1: Moderately satisfied; 2: Somewhat satisfied; 3: Neither satisfied nor dissatisfied; 4: Somewhat dissatisfied; 5: Moderately dissatisfied; 6: Very dissatisfied.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Satisfied With an After Taste in DAQ
ParticipantsFF 110 µgFP 200 µg
Very satisfied712
Moderately satisfied89
Somewhat satisfied37
Neither satisfied nor dissatisfied1115
Somewhat dissatisfied39
Moderately dissatisfied22
Very dissatisfied00
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.434 · Median difference (net): 0.0
SecondaryNumber of Participants Reported Medicine Run Down Throat in IAQ and DAQ

Participant response regarding did the medicine run down throat at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did medicine run down throat? Participants specified their responses on a 6-point scale: 0: None; 1: Very slightly; 2: Slightly; 3: Neither slightly nor moderately; 4: Moderately; 5: Markedly; 6: Very markedly.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Reported Medicine Run Down Throat in IAQ and DAQ
ParticipantsFF 110 µgFP 200 µg
IAQ, None7469
DAQ, None6455
IAQ, Very slightly2829
DAQ, Very slightly3637
IAQ, Slightly1115
DAQ, Slightly1217
IAQ, Neither slightly nor moderately35
DAQ, Neither slightly nor moderately13
IAQ, Moderately33
DAQ, Moderately56
IAQ, Markedly10
DAQ, Markedly31
IAQ, Very markedly10
DAQ, Very markedly01
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.797 · Median difference (net): 0.0
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.296 · Median difference (net): 0.0
SecondaryNumber of Participants Reported Medicine Run Out of Nose in IAQ and DAQ

Participant response regarding did the medicine run out of nose at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did medicine run out of nose? Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Reported Medicine Run Out of Nose in IAQ and DAQ
ParticipantsFF 110 µgFP 200 µg
IAQ, None6138
DAQ, None6346
IAQ, Very slightly4238
DAQ, Very slightly4039
IAQ, Slightly1128
DAQ, Slightly1024
IAQ, Neither slightly nor moderately21
DAQ, Neither slightly nor moderately11
IAQ, Moderately511
DAQ, Moderately74
IAQ, Markedly04
DAQ, Markedly04
IAQ, Very markedly01
DAQ, Very markedly03
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = <0.001 · Median difference (net): 0.0
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = <0.001 · Median difference (net): 0.0
SecondaryNumber of Participants Reported Product Feel Soothing in IAQ and DAQ

Participant response for soothing feel at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ and DAQ having question: Did product feel soothing?. Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Reported Product Feel Soothing in IAQ and DAQ
ParticipantsFF 110 µgFP 200 µg
IAQ, None2824
DAQ, None2625
IAQ, Very slight2831
DAQ, Very slight3431
IAQ, Slight2527
DAQ, Slight2529
IAQ, Neither slight nor moderate1716
DAQ, Neither slight nor moderate1511
IAQ, Moderate1516
DAQ, Moderate1119
IAQ, Marked45
DAQ, Marked56
IAQ, Very marked42
DAQ, Very marked40
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.968 · Median difference (net): 0.0
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.797 · Mean difference (net): 0.0
SecondaryNumber of Participants Reported Product Make Want to Sneeze in IAQ

Participant response regarding sneezing effect at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using IAQ having question: Did product make want to sneeze?. Participants specified their responses on a 6-point scale: 0: No urgency; 1: Very slight urgency; 2: slight urgency; 3: Neither slight nor moderate urgency; 4: Moderate urgency; 5; Marked urgency; 6: Very marked urgency.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Reported Product Make Want to Sneeze in IAQ
ParticipantsFF 110 µgFP 200 µg
No urgency8793
Very slight urgency1712
Slight urgency810
Neither slight nor moderate urgency22
Moderate urgency22
Marked urgency32
Very marked urgency20
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.221 · Median difference (net): 0.0
SecondaryNumber of Participants Satisfied With Product in DAQ

Number of participants responding to product satisfaction with delayed attributes questionnaire, Question: How satisfied with product?. Participants specified their responses on a 6-point scale: 0: very satisfied; 1: moderately satisfied; 2: somewhat satisfied; 3: neither satisfied nor dissatisfied; 4: somewhat dissatisfied; 5; moderately dissatisfied; 6: very dissatisfied.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Satisfied With Product in DAQ
ParticipantsFF 110 µgFP 200 µg
Very satisfied4434
Moderately satisfied2723
Somewhat satisfied1727
Neither satisfied nor dissatisfied1921
Somewhat dissatisfied78
Moderately dissatisfied57
Very dissatisfied20
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.205 · Median difference (net): 0.0
SecondaryNumber of Participants Reported Nasal Irritation in DAQ

Participant response regarding nasal irritation at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: Did product cause nasal irritation?. Participants specified their responses on a 6-point scale: 0: none; 1: very slight; 2: slight; 3: neither slight nor moderate; 4: moderate; 5; marked; 6: very marked.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Reported Nasal Irritation in DAQ
ParticipantsFF 110 µgFP 200 µg
None8978
Very slight1821
Slight610
Neither slight nor moderate23
Moderate37
Marked21
Very marked11
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.108 · Median difference (net): 0.0
SecondaryNumber of Participants Reported Nasal Irritation Bothersome in DAQ

Participant response regarding bothersome of nasal irritation at the end of crossover dosing with FF 110 µg and FP 200 µg was evaluated using DAQ having question: How bothersome was nasal irritation?. Participants specified their responses on a 6-point scale: 0: none; 1: very slightly; 2: slightly; 3: neither slightly nor moderately; 4: moderately; 5; markedly; 6: very markedly.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Reported Nasal Irritation Bothersome in DAQ
ParticipantsFF 110 µgFP 200 µg
None77
Very slightly1522
Slightly98
Neither slightly nor moderately22
Moderately46
Markedly01
Very markedly12
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.694 · Median difference (net): 0.0
SecondaryNumber of Participants Comply With Product if Prescribed in DAQ

Number of participants responding to product attributes using delayed attributes questionnaire, Question: How likely to comply if prescribed?. Participants specified their responses on a 6-point scale: 0: very likely; 1: moderately likely; 2: somewhat likely; 3: neither likely nor unlikely; 4: somewhat unlikely; 5; moderately unlikely; 6: very unlikely.

Time frame:
Day 1
Reported as:
Number · Participants
Number of Participants Comply With Product if Prescribed in DAQ
ParticipantsFF 110 µgFP 200 µg
Very likely6345
Moderately likely1926
Somewhat likely1816
Neither likely nor unlikely710
Slightly unlikely412
Moderately unlikely47
Very unlikely64
Statistical analysis
  • FF 110 µg vs FP 200 µg · Cochran-Mantel-Haenszel · p = 0.020 · Median difference (net): 0.0

Adverse events

Collected over Adverse events were reported throughout the treatment period (Day 1), as this is single day study which included pre treatment, washout, treatment periods 1 and 2. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF 110 µg0/127 (0%)0/127 (0%)3/127 (2.4%)
FP 200 µg0/127 (0%)0/127 (0%)0/127 (0%)
Most frequent other events
Most frequent other events
EventFF 110 µgFP 200 µg
DizzinessNervous system disorders1/1270/127
HeadacheNervous system disorders1/1270/127
Nasal congestionRespiratory, thoracic and mediastinal disorders1/1270/127

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Overall Study Arm
Mean39.7 ± 14.05
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Arm
Female82
Male45
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall Study Arm
Race — African American/African Heritage20
Race — Asian - East Asian Heritage1
Race — Asian - South East Asian Heritage1
Race — Native Hawaiian or other Pacific Islander1
Race — White - Arabic/North African Heritage1
Race — White - White/Caucasian/European Heritage100
Race — Mixed Race2
08

Study locations

14 sites
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Long Beach, California 90808, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    Denver, Colorado 80230, United States
  • GSK Investigational Site
    Lakewood, Colorado 80401, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30045, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    Rolla, Missouri 65401, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Brick, New Jersey 8724, United States
  • GSK Investigational Site
    Skillman, New Jersey 08558, United States
  • GSK Investigational Site
    El Paso, Texas 79925, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2006 to primary completion in Dec 2006, 0 months.

Results were first posted in Jan 2018, 11 years 1 month after primary completion.

Of 17 phase 3 interventional studies under Rhinitis, Allergic, Perennial, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2006
First posted
Nov 10, 2006
StartActual
Dec 1, 2006
Primary completionActual
Dec 4, 2006
CompletionActual
Dec 4, 2006
Results first posted
Jan 29, 2018
Last update
Mar 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00398476
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 10, 2006
Start date
Dec 1, 2006
Primary completion
Dec 4, 2006
Completion
Dec 4, 2006
Results posted
Jan 29, 2018
Last update
Mar 1, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Fluticasone furoate

Start the discussion